Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Greenwich Lifesciences, Inc. (GLSI) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Greenwich Lifesciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1799788.
Total stock buying since 2020: $7,476,244.
Total stock sales since 2020: $0.
Total stock option exercises since 2020: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 34,100 | $350,667 | 0 | $0 | 0 | $0 |
| 2024 | 254,225 | $3,530,221 | 0 | $0 | 0 | $0 |
| 2023 | 51,950 | $583,994 | 0 | $0 | 0 | $0 |
| 2022 | 137,874 | $1,537,689 | 0 | $0 | 0 | $0 |
| 2021 | 3,151 | $85,487 | 0 | $0 | 0 | $0 |
| 2020 | 251,976 | $1,388,186 | 0 | $0 | 2,082,721 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 25,300 | $235,971 | 0 | $0 | 0 | $0 |
| 2025-01 | 8,800 | $114,696 | 0 | $0 | 0 | $0 |
| 2024-11 | 1,000 | $12,910 | 0 | $0 | 0 | $0 |
| 2024-09 | 1,500 | $21,945 | 0 | $0 | 0 | $0 |
| 2024-08 | 9,300 | $126,340 | 0 | $0 | 0 | $0 |
| 2024-07 | 2,500 | $39,835 | 0 | $0 | 0 | $0 |
| 2024-06 | 174,825 | $2,499,997 | 0 | $0 | 0 | $0 |
| 2024-04 | 3,000 | $57,239 | 0 | $0 | 0 | $0 |
| 2024-03 | 38,600 | $510,838 | 0 | $0 | 0 | $0 |
| 2024-02 | 23,500 | $261,117 | 0 | $0 | 0 | $0 |
| 2023-11 | 8,500 | $82,723 | 0 | $0 | 0 | $0 |
| 2023-10 | 8,500 | $70,315 | 0 | $0 | 0 | $0 |
| 2023-09 | 5,600 | $50,506 | 0 | $0 | 0 | $0 |
| 2023-08 | 3,000 | $31,070 | 0 | $0 | 0 | $0 |
| 2023-07 | 1,250 | $11,572 | 0 | $0 | 0 | $0 |
| 2023-05 | 1,000 | $11,690 | 0 | $0 | 0 | $0 |
| 2023-04 | 15,250 | $176,715 | 0 | $0 | 0 | $0 |
| 2023-03 | 1,250 | $15,297 | 0 | $0 | 0 | $0 |
| 2023-02 | 2,100 | $37,656 | 0 | $0 | 0 | $0 |
| 2023-01 | 5,500 | $96,450 | 0 | $0 | 0 | $0 |
| 2022-12 | 8,500 | $120,560 | 0 | $0 | 0 | $0 |
| 2022-11 | 2,000 | $17,580 | 0 | $0 | 0 | $0 |
| 2022-10 | 5,000 | $48,690 | 0 | $0 | 0 | $0 |
| 2022-09 | 4,000 | $37,610 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-25 | Patel Snehal (CEO and CFO) | Buy | 7,200 | 9.88 | 71,136 |
| 2025-04-17 | Patel Snehal (CEO and CFO) | Buy | 5,400 | 8.98 | 48,492 |
| 2025-04-07 | Patel Snehal (CEO and CFO) | Buy | 3,600 | 9.10 | 32,760 |
| 2025-04-04 | Patel Snehal (CEO and CFO) | Buy | 5,500 | 8.73 | 48,015 |
| 2025-01-10 | Patel Snehal (CEO and CFO) | Buy | 2,500 | 12.51 | 31,275 |
| 2025-01-07 | Patel Snehal (CEO and CFO) | Buy | 1,800 | 13.75 | 24,750 |
| 2025-01-06 | Patel Snehal (CEO and CFO) | Buy | 1,100 | 13.31 | 14,641 |
| 2025-01-03 | Patel Snehal (CEO and CFO) | Buy | 3,400 | 12.95 | 44,030 |
| 2024-11-21 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 1,000 | 12.91 | 12,910 |
| 2024-09-26 | Patel Snehal (CEO and CFO) | Buy | 1,500 | 14.63 | 21,945 |
| 2024-08-12 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 800 | 13.85 | 11,080 |
| 2024-08-06 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 13.81 | 27,620 |
| 2024-08-05 | Patel Snehal (CEO and CFO) | Buy | 5,500 | 13.18 | 72,490 |
| 2024-08-02 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 1,000 | 15.15 | 15,150 |
| 2024-07-23 | Patel Snehal (CEO and CFO) | Buy | 1,500 | 15.89 | 23,835 |
| 2024-07-18 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 1,000 | 16.00 | 16,000 |
| 2024-06-13 | Patel Snehal (CEO and CFO) | Buy | 174,825 | 14.30 | 2,499,997 |
| 2024-04-01 | Patel Snehal (CEO and CFO) | Buy | 3,000 | 19.08 | 57,239 |
| 2024-03-22 | Patel Snehal (CEO and CFO) | Buy | 2,500 | 19.98 | 49,950 |
| 2024-03-20 | Patel Snehal (CEO and CFO) | Buy | 1,500 | 17.68 | 26,520 |
| 2024-03-05 | Patel Snehal (CEO and CFO) | Buy | 30,500 | 12.49 | 380,945 |
| 2024-03-04 | Patel Snehal (CEO and CFO) | Buy | 4,100 | 13.03 | 53,423 |
| 2024-02-16 | Patel Snehal (CEO and CFO) | Buy | 10,800 | 11.16 | 120,528 |
| 2024-02-15 | Patel Snehal (CEO and CFO) | Buy | 12,700 | 11.07 | 140,589 |
| 2023-11-10 | Patel Snehal (CEO and CFO) | Buy | 5,000 | 10.17 | 50,839 |
| 2023-11-03 | Patel Snehal (CEO and CFO) | Buy | 3,500 | 9.11 | 31,884 |
| 2023-10-27 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 500 | 8.57 | 4,285 |
| 2023-10-26 | Patel Snehal (CEO and CFO) | Buy | 2,500 | 7.97 | 19,925 |
| 2023-10-25 | Patel Snehal (CEO and CFO) | Buy | 2,500 | 7.91 | 19,775 |
| 2023-10-10 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 9.07 | 9,070 |
| 2023-10-04 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 8.63 | 17,260 |
| 2023-09-26 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 600 | 8.71 | 5,226 |
| 2023-09-19 | Patel Snehal (CEO and CFO) | Buy | 4,000 | 8.95 | 35,800 |
| 2023-09-11 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 9.48 | 9,480 |
| 2023-08-22 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 9.97 | 9,970 |
| 2023-08-04 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 10.55 | 21,100 |
| 2023-07-21 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 9.20 | 9,200 |
| 2023-07-13 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 9.49 | 2,372 |
| 2023-05-17 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 11.69 | 11,690 |
| 2023-04-28 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 11.22 | 2,805 |
| 2023-04-19 | Patel Snehal (CEO and CFO) | Buy | 7,000 | 11.10 | 77,700 |
| 2023-04-18 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 11.12 | 22,240 |
| 2023-04-11 | Patel Snehal (CEO and CFO) | Buy | 5,000 | 12.42 | 62,100 |
| 2023-04-11 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 1,000 | 11.87 | 11,870 |
| 2023-03-15 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 12.71 | 3,177 |
| 2023-03-10 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 12.12 | 12,120 |
| 2023-02-24 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 15.39 | 3,848 |
| 2023-02-17 | Patel Snehal (CEO and CFO) | Buy | 600 | 16.53 | 9,918 |
| 2023-02-10 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 18.68 | 18,680 |
| 2023-02-03 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 20.84 | 5,210 |
| 2023-01-27 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 19.35 | 38,700 |
| 2023-01-27 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 19.20 | 4,800 |
| 2023-01-20 | Patel Snehal (CEO and CFO) | Buy | 1,500 | 17.37 | 26,055 |
| 2023-01-13 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 16.50 | 4,125 |
| 2023-01-06 | Patel Snehal (CEO and CFO) | Buy | 1,500 | 15.18 | 22,770 |
| 2022-12-29 | Patel Snehal (CEO and CFO) | Buy | 4,000 | 15.19 | 60,760 |
| 2022-12-16 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 13.01 | 13,010 |
| 2022-12-16 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 12.94 | 3,235 |
| 2022-12-09 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 13.11 | 26,220 |
| 2022-12-02 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 13.84 | 13,840 |
| 2022-12-02 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 250 | 13.98 | 3,495 |
| 2022-11-02 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 8.79 | 17,580 |
| 2022-10-14 | Patel Snehal (CEO and CFO) | Buy | 3,000 | 9.75 | 29,250 |
| 2022-10-07 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 9.72 | 19,440 |
| 2022-09-30 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 9.46 | 18,920 |
| 2022-09-29 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 9.23 | 9,230 |
| 2022-06-24 | Patel Snehal (CEO and CFO) | Buy | 29,000 | 9.13 | 264,770 |
| 2022-06-16 | Patel Snehal (CEO and CFO) | Buy | 8,000 | 7.13 | 57,040 |
| 2022-06-14 | Patel Snehal (CEO and CFO) | Buy | 12,000 | 7.91 | 94,920 |
| 2022-06-10 | Patel Snehal (CEO and CFO) | Buy | 12,000 | 8.33 | 99,960 |
| 2022-06-09 | Patel Snehal (CEO and CFO) | Buy | 4,500 | 10.90 | 49,050 |
| 2022-06-07 | Patel Snehal (CEO and CFO) | Buy | 6,000 | 8.55 | 51,300 |
| 2022-06-03 | Patel Snehal (CEO and CFO) | Buy | 9,250 | 8.35 | 77,237 |
| 2022-06-02 | Patel Snehal (CEO and CFO) | Buy | 6,774 | 7.38 | 49,992 |
| 2022-04-25 | Daugherty Frank Joseph (Chief Medical Officer) | Buy | 1,000 | 16.25 | 16,250 |
| 2022-04-21 | Patel Snehal (CEO and CFO) | Buy | 6,000 | 16.09 | 96,540 |
| 2022-04-19 | Patel Snehal (CEO and CFO) | Buy | 6,000 | 16.74 | 100,439 |
| 2022-04-19 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 500 | 16.74 | 8,370 |
| 2022-02-11 | Patel Snehal (CEO and CFO) | Buy | 5,500 | 19.80 | 108,900 |
| 2022-02-04 | Patel Snehal (CEO and CFO) | Buy | 5,000 | 19.59 | 97,950 |
| 2022-01-31 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 500 | 18.47 | 9,235 |
| 2022-01-21 | Hallock Kenneth | Buy | 300 | 16.32 | 4,896 |
| 2022-01-21 | Thompson Jaye (VP Clinical Reg Affairs) | Buy | 500 | 16.33 | 8,164 |
| 2022-01-18 | Thompson Jaye (VP Clinical Reg. Affairs) | Buy | 500 | 18.87 | 9,435 |
| 2022-01-13 | Patel Snehal (CEO and CFO) | Buy | 1,000 | 19.99 | 19,990 |
| 2022-01-13 | Daugherty Frank Joseph (Chief Medical Officer) | Buy | 1,000 | 19.99 | 19,990 |
| 2022-01-13 | Thompson Jaye (VP Clinical Reg. Affairs) | Buy | 1,000 | 19.99 | 19,990 |
| 2022-01-03 | Patel Snehal (CEO and CFO) | Buy | 2,050 | 23.82 | 48,831 |
| 2021-12-14 | Patel Snehal (CEO and CFO) | Buy | 1,840 | 27.17 | 49,992 |
| 2021-12-14 | Daugherty Frank Joseph (Chief Medical Officer) | Buy | 1,111 | 26.99 | 29,983 |
| 2021-12-14 | Mcwilliams David | Buy | 200 | 27.56 | 5,512 |
| 2020-11-24 | Hallock Kenneth | Buy | 1,000 | 5.39 | 5,386 |
| 2020-11-23 | Daugherty Frank Joseph (Chief Medical Officer) | Buy | 1,000 | 5.10 | 5,100 |
| 2020-11-20 | Hallock Kenneth | Buy | 1,000 | 5.37 | 5,370 |
| 2020-11-20 | Rothe Eric | Buy | 2,000 | 5.40 | 10,800 |
| 2020-11-20 | Mcwilliams David | Buy | 1,500 | 5.40 | 8,100 |
| 2020-11-19 | Patel Snehal (CEO and CFO) | Buy | 2,000 | 5.40 | 10,796 |
| 2020-09-29 | Patel Kinnary | Option Ex | 129,400 | .00 | 0 |
| 2020-09-29 | Hallock Kenneth | Buy | 83,115 | 5.18 | 468,352 |
| 2020-09-29 | Hallock Kenneth | Option Ex | 116,575 | .00 | 0 |
| 2020-09-29 | Patel Snehal (CEO and CFO) | Buy | 131,014 | 5.18 | 734,213 |
| 2020-09-29 | Patel Snehal (CEO and CFO) | Option Ex | 1,665,124 | .00 | 0 |
| 2020-09-29 | Daugherty Frank Joseph (Chief Medical Officer) | Buy | 1,739 | 5.75 | 9,999 |
| 2020-09-29 | Mcwilliams David | Buy | 2,608 | 5.75 | 14,996 |
| 2020-09-29 | Mcwilliams David | Option Ex | 171,622 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of GLSI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Greenwich Lifesciences, Inc. (symbol GLSI, CIK number 1799788) see the Securities and Exchange Commission (SEC) website.